What Вазостенон Treats: Main Uses and Benefits

Вазостенон is applied across domains where additional symptomatic support is needed. Its therapeutic scope is relevant in contexts involving heightened systemic burden and symptomatic distress. The medication is applied in addressing symptom clusters that may become intense or disruptive, relevant in conditions characterized by periods of heightened symptoms.

It is commonly used across conditions presenting with systemic or localized discomfort and symptoms that create noticeable physiological strain. It is relevant for easing symptomatic discomfort during phases where a patient experiences heightened discomfort due to an episode or acute presentation. It may assist patients with maintaining functional stability during difficult episodes.

“The therapy is applied across domains where additional symptomatic support is needed, contributing to easing the overall symptom load.”

Quick Fact: Supportive Assistance for Acute Symptom Manifestations

Вазостенон is often used during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

1. Irish Health Products Regulatory Authority (HPRA) leaflet

Eligibility Map: Who can and cannot use Вазостенон

The eligibility profile for Вазостенон (Alprostadil) is strictly defined by regulatory documents and segmented by indication, age, and pre-existing health conditions.

Populations for Whom Use is Allowed

Age Group	Indication	Regulatory Rule
Adult Men (≥18)	Treatment of erectile dysfunction (ED).	Approved use.
Neonates	Temporary maintenance of ductus arteriosus patency.	Approved use for specific heart defects.

Populations for Whom Use is Contraindicated (Absolute Prohibitions)

The medicine must not be used in patients with a known hypersensitivity to alprostadil or any excipients. Use is formally contraindicated for the following groups:

• Patients with conditions that predispose to priapism, including sickle cell anemia or leukemia.
• Men with penile implants or anatomical deformation of the penis (e.g., Peyronie's disease) for ED treatment.
• Neonates with Respiratory Distress Syndrome.
• Women (for the ED indication).

Age and Organ Function Restrictions

• Children and Adolescents: Use for ED is not indicated and safety has not been established.
• Older Adults (Geriatric): Use requires caution due to potential age-related changes in kidney function.
• Renal/Hepatic Impairment: Formal studies are insufficient; use requires caution and may necessitate potential dose adjustment.

Interactions with other medicines and products

This section describes formally documented interaction patterns for Вазостенон (Alprostadil) as defined in government regulatory labeling. Interaction effects are primarily classified as pharmacodynamic, focusing on the combination of effects on blood pressure and coagulation.

Pharmacodynamic Interaction Patterns

Category of Interacting Product	Officially Documented Interaction Outcome
Antihypertensive Drugs and Vasoactive Medications	Co-administration may result in an increased risk of systemic hypotension due to additive vasodilating effects.
Anticoagulants (e.g., Warfarin, Heparin)	Use with these products increases the risk of bleeding or hemorrhage due to Alprostadil's intrinsic anti-platelet activity.
Platelet Aggregation Inhibitors (e.g., Aspirin)	Concomitant use increases the risk of local or injection-site bleeding.
Phosphodiesterase-5 (PDE5) Inhibitors	Combination is generally not recommended in regulatory labeling due to the increased, non-studied cardiovascular risk.

Pharmacokinetic and Substance Interactions

The potential for pharmacokinetic drug-drug interactions, including those mediated by Cytochrome P450 (CYP) enzymes, is noted in official documentation as not formally studied due to Alprostadil's rapid local metabolism. No specific timing rules are documented that mandate separation of administration from other medicinal products.

Population-Specific Notes

The risk of hypotension resulting from co-administration with blood pressure-lowering medicines may be more pronounced in the elderly. Some intravenous formulations contain ethanol, which necessitates careful consideration when used with other ethanol-containing medicines, particularly in neonates, to avoid the risk of accumulation.

How Вазостенон Works

Вазостенон's mechanism begins with the direct agonism of specific Prostaglandin E1 Receptors (primarily EP2 and EP4 subtypes) on vascular smooth muscle and platelet membranes. Receptor activation initiates a Gs protein-coupled signaling cascade by stimulating the enzyme adenylate cyclase. This action increases the concentration of the intracellular messenger cyclic adenosine monophosphate ( cAMP).

In arterial smooth muscle, elevated cAMP promotes relaxation by reducing the level of intracellular calcium ions ( Ca^2+). This mechanistic cascade results in arterial smooth muscle relaxation and a measurable reduction in vascular resistance. Concurrently, the same cAMP increase in platelets acts as a negative regulator, suppressing the function of the Glycoprotein IIb/IIIa receptor complex, thereby modulating the pathway of platelet aggregation.

The mechanism is functionally constrained by rapid and extensive pulmonary metabolism (up to 80% clearance in one pass), which imposes a need for continuous administration to sustain receptor agonism.

The administration of Вазостенон (Alprostadil) is governed by strict protocols tailored to the specific context of use. The medicine is exclusively administered via parenteral routes—either as an injection for adult use or as a continuous infusion for neonatal applications.

Official Administration Guidelines

Instruction Domain	Description of Labeled Use
Route & Frequency	Adult administration is via intracavernosal injection, limited to no more than three times weekly, with a mandatory minimum of 24 hours between doses.
Adult Dosing & Titration	Initial intracavernosal doses start at 2.5 mcg for most etiologies, with the maximum recommended dose not exceeding 60 mcg. The first dose and titration must be performed in a healthcare provider’s office.
Preparation Requirements	The lyophilized powder formulation must be reconstituted using the supplied diluent immediately prior to use; the product is strictly designated for single use only.
Neonatal Administration	For neonatal applications, the medicine is administered as a continuous IV infusion, starting typically at 0.05 to 0.1 mcg/kg/minute. The rate is reduced to the lowest effective dosage once a therapeutic response is achieved. This procedure requires a specialized setting with access to supportive care.

These protocols collectively structure the use of the drug, defining when, how, and where the medicine must be administered to ensure adherence to official guidelines. This dual-route approach—injection or continuous infusion—and mandatory initial supervision are central to the official procedural framework.

Research Evidence / Overview of Studies for Вазостенон (Alprostadil)

---

Evidence for use in Critical Limb Ischemia and Advanced PAOD

The active ingredient in Вазостенон, Alprostadil, was studied for its presence in research exploring its application in advanced Peripheral Arterial Occlusive Disease (PAOD), particularly in severe cases known as Critical Limb Ischemia (CLI). This research focuses on patients facing significant functional limitations and severe symptoms, often those who have limited or no access to surgical options to restore blood flow in the affected limbs.

The core evidence is derived from a number of Randomized Controlled Trials (RCTs). These studies explored the patterns of outcomes related to physical discomfort and the frequency of major amputation in the observed populations. Researchers focused on measuring changes in the intensity of severe rest pain and the rate of complete healing of ischemic ulcers. The primary, high-level measurement was observed in studies for the frequency of major amputation.

What Clinical Trials and Systematic Reviews Examined

Clinical trials and systematic reviews studies explored whether patterns related to the rate of major amputation were observed in treated groups compared to control groups receiving inactive treatment (placebo). Research explored the frequency of this outcome. Findings were mixed across the evidence base. Studies reported measurements of changes in perfusion values and changes in the consumption of analgesic medication. This evidence contributes to understanding symptom patterns, but the overall consistency of the research findings evidence quality varies across studies.

---

Long-Term Studies and Follow-Up Data

The research landscape includes data gathered from both short-term clinical trials and longer-term observational follow-up studies. The initial treatment phases studies monitored patient responses over short time intervals, often up to 4 to 12 weeks.

For outcomes reflecting daily functioning, some research has explored outcomes up to one year and beyond. These extended observations research describes patterns related to survival without major amputation in the studied cohorts. The follow-up durations were limited in high-quality RCTs, and the data for long-term outcomes remains insufficient from high-quality RCTs.

---

Evidence in Specific Patient Populations

Research examined specific high-risk patient populations. Studies examined outcomes in patients with diabetic mellitus, a group often facing severe vascular problems, and those who cannot undergo revascularization surgery. Evidence is limited for these special populations. However, the sample sizes were modest in these specific subgroup analyses, and the results apply only to the populations studied.

---

What Remains Uncertain in the Research Landscape

A key limitation is the inconsistent findings reported across several large clinical trials when assessing the frequency of amputation in treated groups compared to placebo. Furthermore, the existing evidence base is limited by the age of many of the core studies, meaning that much of the available data was gathered under historical research methodologies. For several key outcomes, certainty remains low based on the available data. Research gaps persist in the broader evidence landscape.

Common questions about Вазостенон (FAQ)

Q: Can I take Vasostenon if I have liver problems?

A: Official documentation indicates that the medicine should be used with caution in patients who have existing liver problems, which is known as hepatic impairment. Regulatory sources also note that formal studies specifically examining the use of the medicine in patients with significant kidney or liver issues are insufficient.

Q: Is Vasostenon allowed for use in older adults?

A: Official product information notes that use in the geriatric (older adult) population requires caution. This is generally due to the potential for age-related changes in body functions, such as changes in kidney or liver function, which may necessitate a possible dose adjustment.

Q: Does Vasostenon affect potency or libido?

A: Vasostenon (Alprostadil) is officially approved for the treatment of erectile dysfunction (ED) in adult men; therefore, its core mechanism directly promotes an erection (potency). However, effects on overall sexual desire (libido) are not detailed or discussed in official regulatory product labeling.

Q: What is known about the use of Vasostenon in children?

A: Use in neonates (newborns) is described as an approved indication for the temporary maintenance of the patency of the ductus arteriosus in specific heart defects. For the treatment of erectile dysfunction, use in children and adolescents (under 18) is not indicated, and safety has not been established.

Q: How quickly does Vasostenon start working after the start of administration?

A: For the treatment of erectile dysfunction, clinical study data show that the effect, such as penile rigidity, may be achieved within 5 to 30 minutes following the injection. The duration of the achieved effect typically lasts less than one hour due to the medicine's rapid metabolism in the body.

Q: Can I drink coffee or alcohol during a Vasostenon course?

A: Official patient information regarding alcohol use often mentions the need for consultation with a healthcare provider. Some sources suggest alcohol may decrease the overall effectiveness of the treatment or could increase the risk of systemic side effects like dizziness.

Q: What happens if I miss a dose of Vasostenon?

A: The official administration guidelines for the injection specify the recommended frequency is no more than three times weekly, with a stated minimum interval of 24 hours between doses. The guidelines do not contain specific instructions for a 'missed dose' but emphasize adherence to the maximum frequency limits.

Q: Does Vasostenon affect the results of laboratory blood tests?

A: Alprostadil is officially indicated as an adjunct (an addition) to other diagnostic tests, such as duplex or Doppler imaging, in the diagnosis of erectile dysfunction. Its direct effect on standard blood chemistry panels is not detailed in official regulatory labeling.

Q: Why does Vasostenon sometimes not help as expected?

A: Clinical research evidence for the active ingredient has included reports of inconsistent findings across certain trials for some outcomes. Official information notes that the medicine may not be effective in patients with specific underlying conditions, such as cavernosal venous leakage, a condition that can result in insufficient response.

Q: Are there restrictions on driving a car while taking Vasostenon?

A: Regulatory documents advise caution for activities like driving or operating machinery. Reported side effects such as dizziness or syncope (fainting) have the potential to temporarily impair abilities necessary for these tasks.

Q: What are the generally accepted expectations from Vasostenon treatment?

A: For its main indication, the expected outcome is to produce an erection suitable for intercourse that does not exceed a duration of one hour. In other approved applications, the therapeutic goal is to improve arterial and peripheral perfusion or maintain patency of the ductus arteriosus in infants.

Q: Can Vasostenon be taken for a long time (more than a year)?

A: Regulatory documents include a warning that the risk of penile fibrosis (the development of fibrous tissue) is noted to increase with prolonged use or long-term exposure. The duration of use is typically assessed by a healthcare provider due to the known risks.

Q: Why does Vasostenon come in injection and tablet form?

A: Official regulatory documents only list the dosage form as a Sterile Powder for Injection or a Solution for Injection. The medicine is not available in a tablet form, which suggests that the mention of a 'tablet form' is likely based on user misunderstanding or confusion with a different product.

Q: Why is Vasostenon not sold without a prescription?

A: The medicine is classified as a prescription-only drug. This status is typically based on the requirement for complex parenteral administration (non-oral routes) and the necessity for the initial dose and titration to be performed and monitored in a healthcare provider’s office to ensure safe use.

Q: Some people get nausea from Vasostenon, is that normal?

A: Nausea is generally not listed as a very common (ge 10%) or common (1-10%) side effect in the official regulatory documents for the injectable forms. While some official patient-focused information may mention nausea, it is not a highly prevalent documented adverse event.

Q: What vitamins or supplements might affect Vasostenon's action?

A: While the core drug label focuses on prescription drug interactions, official screening tools may flag certain supplements or vitamins for potential interactions with Alprostadil. These are often classified as having a minor or unknown potential for interaction, and comprehensive lists of every supplement are generally not included in the core label.

Q: Why do doctors prescribe Vasostenon for different problems?

A: The medicine is classified as a potent Vasodilator and Prostaglandin Analog. This single mechanism of promoting smooth muscle relaxation and increasing blood flow is effective and necessary in several distinct medical conditions, leading to multiple, officially approved indications across different medical fields.

Q: How does Vasostenon interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?

A: Official regulatory documents warn that the medicine increases the risk of local or injection-site bleeding when used concomitantly with Platelet Aggregation Inhibitors (like aspirin). Certain NSAIDs also possess anti-platelet activity, and caution may be advised due to the potential for similar effects.

Q: Why was Vasostenon prescribed to me even though I don't have the main disease?

A: Official documentation lists multiple approved indications, including the treatment of erectile dysfunction (ED) in adult men and the use in neonates. The medicine is approved for multiple different conditions. Its use is based on the indications officially recognized for the drug's mechanism of action.

Q: Does food intake affect the absorption of Vasostenon?

A: The most common routes of administration are intracavernosal injection or continuous intravenous infusion. Since these are parenteral (non-oral) routes, the medicine is delivered directly into the circulation or targeted tissue, which typically means that its absorption is not affected by food or meal timing.

Q: Are there restrictions on playing sports during Vasostenon treatment?

A: Official documents mention the potential for side effects such as dizziness or syncope (fainting), which may impact the safety of engaging in certain activities. For the ED indication, official information also requires consideration of the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease.

Q: Is Vasostenon a hormonal drug or not?

A: The medicine is a synthetic analog of the endogenous substance Prostaglandin E1 ( PGE1). While PGE1 is a naturally produced, hormone-like signaling molecule, the drug itself is officially classified as a Vasodilator and Prostaglandin Analog, not a steroid hormone.

Storage and Disposal Requirements

Official regulatory guidelines for Вазостенон (Alprostadil) define specific conditions for product stability and safety. The unopened medication must be stored at controlled room temperature, typically below 25 C or 77 F. It is strictly required that the product be kept in its original container, protected from light, and must not be frozen.

Condition	Regulatory Requirement
Temperature	Store below 25 C (Do not freeze)
Container	Keep in original packaging
Child Safety	Keep out of the sight and reach of children
Disposal	Do not discard in household trash or wastewater

Once reconstituted, the solution must be used immediately, or within a maximum of 24 hours depending on the specific product label, and any unused portion must be discarded. Used needles and syringes must be placed in a designated sharps disposal container and disposed of according to local pharmaceutical waste regulations.